TIDMEVG

RNS Number : 6642S

Evgen Pharma PLC

13 March 2023

Evgen Pharma plc

("Evgen" or the "Company")

No exposure to Silicon Valley Bank

Alderley Park, UK - 13 March 2023 : Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines for the treatment of cancer and other indications, notes the financial problems at the US and UK arms of Silicon Valley Bank (SVB).

Evgen confirms that it is has neither deposits, loans nor any other financial instrument with any part of SVB.

-Ends-

Enquiries:

 
 Evgen Pharma plc                         Tel: +44 1625 466591 
  Dr Huw Jones, CEO 
  Richard Moulson, CFO 
 FinnCap (Nominated Advisor and          Tel: +44 20 7220 0500 
  Broker) 
  Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
  Alice Lane/ Nigel Birks (ECM) 
                                        ---------------------- 
 Instinctif Partners                     Tel: +44 207 457 2020 
  Melanie Toyne-Sewell / Rozi Morris      Evgen@Instinctif.com 
  / Adam Loudon 
                                        ----------------------

Notes to Editors

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer. In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core area, Evgen signed an out-licensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex(R) technology. Evgen also has a licensing deal with Stalicla SA in neurodevelopmental disorders and schizophrenia.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCJTMBTMTBBTIJ

(END) Dow Jones Newswires

March 13, 2023 03:00 ET (07:00 GMT)

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Evgen Pharma
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Evgen Pharma